Outlook Therapeutics (OTLK) Gains from Investment Securities: 2015-2024
Historic Gains from Investment Securities for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to -$38.6 million.
- Outlook Therapeutics' Gains from Investment Securities rose 110.51% to $18,115 in Q3 2020 from the same period last year, while for Sep 2020 it was -$2.1 million, marking a year-over-year increase of 14.43%. This contributed to the annual value of -$38.6 million for FY2024, which is 18657.87% down from last year.
- Latest data reveals that Outlook Therapeutics reported Gains from Investment Securities of -$38.6 million as of FY2024, which was down 18,657.87% from $208,203 recorded in FY2023.
- Outlook Therapeutics' 5-year Gains from Investment Securities high stood at $452,146 for FY2021, and its period low was -$38.6 million during FY2024.
- Moreover, its 3-year median value for Gains from Investment Securities was -$465,780 (2022), whereas its average is -$13.0 million.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 144.70% in 2023, then slumped by 18,657.87% in 2024.
- Yearly analysis of 5 years shows Outlook Therapeutics' Gains from Investment Securities stood at $215,074 in 2020, then soared by 110.23% to $452,146 in 2021, then tumbled by 203.02% to -$465,780 in 2022, then skyrocketed by 144.70% to $208,203 in 2023, then tumbled by 18,657.87% to -$38.6 million in 2024.